GSK - NYSE - Nasty Chart, looks like a test of the 2012 low is coming. GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the [...]
Since its lows in mid-October, biotech stocks have sparkled, particularly the Big four – Amgen (AMGN), Biogen Idec (BIIB), Celgene (CELG), and Gilead (GILD) – which have demonstrated sustainable growth pathways. With the market’s renewed volatility in recent days, they have pulled back some, which only made them much more reasonably priced. But the more [...]
We have bad news and good news about patent expirations next year. The bad? When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. That year, $53 billion worth of drugs fell off patent--and many drugmakers are [...]
Anyone who's watched a Viagra commercial knows that Pfizer ($PFE) isn't too embarrassed to talk about sex. Anyone who's run across Pfizer's "Get Old" campaign knows it doesn't shy away from aging, either. Now, the drug giant is going equal opportunity on the sex-and-aging talk, and "Desperate Housewives" actress Brenda Strong has the dialogue. With [...]
(Reuters) - Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. The shares jumped about to $40 in extended trading after closing at $25.09 on Nasdaq. Patients administered [...]
This is a nasty chart. Considering this is the major Russian Market Index, it is even nastier. The Rubel is sliding and interest rates are 17%. I don't really practice economics anymore, but this smells a bit like 2007. Don't take this as negativity, just signs of cracks in the foundation.
Shares of Isis Pharmaceuticals closed Friday at an all-time high of $62.32. Isis edged up 45 cents for the day, nosing out the previous record of $61.87, reached Thursday. The Carlsbad biotech is up 63 percent from a year ago, and more than six times its price on Dec. 12, 2012, when it closed at [...]
U.S. crude oil prices sold off another 3.3% Monday to the lowest level since July 2009 after OPEC hinted it won't cut its production targets despite swelling supplies. Even though you are paying less at the pump, this is not good for anyone. Plummeting oil, gold, agricultural smells like deflation and deflation is a killer [...]
Tony Coles, the chief executive who sold Onyx Pharmaceuticals to Amgen AMGN -2.45% for $10.4 billion in 2013, is starting a new company that will use yeast to try and discover new treatments for Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease.) The new startup, Yumanity, will be based in [...]
Teva stalled out? Maybe? Like the rest of the space, TEVA has had a nice ride, but maybe time to step aside. See the article and chart. Don't be surprised if Teva's ($TEVA) revenue numbers don't meet analysts' expectations in 2015. According to the company's forecasts, generic competition to top-seller Copaxone and foreign currency [...]
